Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company focused on minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. This news page aggregates company announcements, clinical updates, and financial disclosures so readers can follow how Inspire therapy and the Inspire V system are progressing in clinical practice and the marketplace.
Inspire regularly issues earnings releases and financial guidance, including preliminary and unaudited revenue ranges, full-year outlooks, and discussions of non-GAAP measures such as adjusted net income and adjusted EBITDA. Investors can track how revenue tied to Inspire therapy evolves over time, as well as information about share repurchase authorizations and tax-related items disclosed in Form 8-K filings and accompanying press releases.
Because Inspire’s core business is neurostimulation-based treatment for moderate to severe obstructive sleep apnea, a significant portion of its news flow centers on clinical data and product evolution. The company publishes outcomes from studies of the Inspire V system, including procedure success rates, reductions in disease severity, and patient adherence, and presents these results at medical meetings such as the American Academy of Otolaryngology–Head and Neck Surgery and the International Surgical Sleep Society.
Corporate governance and leadership changes are also covered, including announcements about the transition of the Chief Financial Officer role, executive employment agreements, and retirement plans for senior leaders. In addition, Inspire frequently reports on its participation in major healthcare and investor conferences, where management discusses business performance, reimbursement developments, and strategic priorities.
By reviewing this news feed, followers of INSP stock can see how Inspire communicates its financial performance, clinical evidence, regulatory and reimbursement context, and leadership decisions over time, all drawn from company-issued releases and related SEC filings.
Inspire Medical Systems, a leader in medical technology for obstructive sleep apnea, has announced its upcoming presentation at the virtual Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 3:50 p.m. Eastern Time. The event will be accessible via a live webcast, which can be found here. A replay will be available for two weeks afterward on Inspire's Investor website. The company offers Inspire therapy, the only FDA-approved neurostimulation technology for effectively treating moderate to severe obstructive sleep apnea.
Inspire Medical Systems (NYSE: INSP) will present at the virtual UBS Global Healthcare Conference on May 20, 2020, at 10:00 a.m. Eastern Time. The live presentation will be accessible through a webcast, with a replay available for two weeks afterward on Inspire’s Investor website. Inspire is a medical technology company specializing in innovative solutions for obstructive sleep apnea, including the first FDA-approved neurostimulation therapy for moderate to severe cases. For more information, visit www.inspiresleep.com.
Inspire Medical Systems (INSP) reported Q1 2020 revenue of $21.3 million, a 31% increase year-over-year. U.S. revenue rose 34% to $19.3 million, while European revenue increased 9% to $2.1 million. The company activated 28 new medical centers, reaching a total of 327, and completed a public offering raising $124.7 million in April. However, the COVID-19 pandemic led to postponements of implant procedures, significantly impacting operations. Inspire withdrew its full-year guidance due to uncertainties surrounding the pandemic.
Summary not available.
Summary not available.